ERBB2 and gastric cancer: In patients with HER2-positive advanced GC, the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated that the addition of trastuzumab, an anti-HER2 monoclonal antibody, to chemotherapy was significantly beneficial17.